Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?

Enhancer of Zeste Homolog 2 (EZH2) plays an essential epigenetic role in Diffuse Large B Cell Lymphoma (DLBCL) development. Recurrent somatic heterozygous gain-of-function mutations of EZH2 have been identified in DLBCL, most notably affecting tyrosine 641 (Y641), inducing hyper-trimethylation of H3...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Dubois, Sydney, Mareschal, Sylvain, Picquenot, Jean-Michel, Viailly, Pierre-Julien, Bohers, Elodie, Cornic, Marie, Bertrand, Philippe, Veresezan, Elena Liana, Ruminy, Philippe, Maingonnat, Catherine, Marchand, Vinciane, Lanic, Hélène, Penther, Dominique, Bastard, Christian, Tilly, Hervé, Jardin, Fabrice
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2015
Témata:
Clinical Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599301/
https://ncbi.nlm.nih.gov/pubmed/25762637
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky